Medicine and Dentistry
Neoplasm
98%
Organoid
73%
Endometrial Cancer
64%
T Cell
56%
Kidney Graft
48%
Xerostomia
48%
Disease
46%
Progenitor Cell
44%
Malignant Neoplasm
44%
Salivary Gland
43%
B Cell
43%
Uterine Cancer
41%
Recurrent Disease
38%
Recurrence Risk
38%
Cohort Analysis
36%
Quality of Life
36%
Stem Cell
34%
Immune Response
32%
Immune Checkpoint Inhibitor
32%
DNA Mismatch Repair
32%
Arm
32%
Granulosa Cell Tumour
32%
Immune Disorder
32%
Parotid Gland
31%
In Vitro
31%
Medicine
30%
Radiation Therapy
29%
Side Effect
28%
Submandibular Gland
28%
Primary Central Nervous System Lymphoma
27%
Dendritic Cell
26%
Autologous Stem Cell Transplantation
26%
Stem Cell
24%
Pembrolizumab
22%
Head and Neck Cancer
22%
Positron Emission Tomography
21%
Cancer Immunotherapy
21%
Overall Survival
21%
Prospective Study
20%
Personalized Medicine
20%
Cell Therapy
20%
Serositis
20%
Infection
19%
Protein P53
19%
Magnetic Resonance Imaging
19%
Cancer Cell
19%
Cell Function
19%
Ovarian Cancer
18%
Immunity
18%
Microglia
18%
Immunotherapy
18%
Diagnostic Accuracy
17%
Cancer Registry
17%
Cyclophosphamide
17%
Doxorubicin
17%
Drug Megadose
17%
Protein Depletion
16%
Retinoblastoma Protein
16%
Endometrium Carcinoma
16%
Brentuximab Vedotin
16%
Circulating Tumor DNA
16%
Cytotoxicity
16%
Tumor Metabolism
16%
Combination Chemotherapy
16%
Molecular Pathology
16%
Antibodies
16%
Lymphoma Cell
16%
Mantle Cell Lymphoma
16%
Burkitt's Lymphoma
16%
Genomic Instability
16%
microRNA
16%
Iron Deficiency
16%
Methotrexate
16%
Hyperglycemia
16%
Immune Checkpoint Blockade
16%
Cell Free DNA
16%
Ibrutinib
16%
Memory B Cell
16%
Buthionine Sulfoximine
16%
Anemia
16%
Tumor Immunity
16%
Muscle Strength
16%
Peripheral T-Cell Lymphoma
16%
Enzyme Active Site
16%
Large Granular Lymphocytic Leukemia
16%
Droplet Digital Polymerase Chain Reaction
16%
Krukenberg Tumor
16%
Nodular Melanoma
16%
Patient-Reported Outcome
16%
Diagnostic Marker
16%
Classical Hodgkin Lymphoma
16%
Hypochromic Anemia
16%
Glutamate Cysteine Ligase
16%
Memory T Cell
16%
Diffuse Large B-Cell Lymphoma
16%
Cardiopulmonary Function
16%
Scatter Factor Receptor
16%
Cell Line
16%
Lymph Node Metastasis
16%
Autotransplantation
16%
Keyphrases
Endometrial Cancer
73%
Tumor
65%
Radiotherapy
53%
Immune Checkpoint Inhibitors
50%
Genomic Instability
38%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
34%
Kidney Transplant Recipients
32%
Mismatch Repair
32%
Survival Outcomes
32%
Large B-cell Lymphoma
32%
Neoadjuvant
32%
Diagnostic Accuracy
32%
Organoids
32%
Radiation-induced Xerostomia
32%
B Cells
32%
Health-related Quality of Life
31%
Salivary Gland
27%
Patient Well-being
24%
Stem Progenitor Cells
23%
Pembrolizumab
22%
Replication Stress
22%
Clinical Grade
21%
Xerostomia
21%
Early Effect
21%
Overall Survival
21%
Netherlands
21%
Salivary Gland Organoids
20%
Head-and-neck Cancer
20%
Axicabtagene Ciloleucel
20%
Cyclin E1
20%
Sigma Phase
19%
Biobank
19%
Metabolic
19%
Clinical Application
19%
Tumor Volume
19%
Normal Tissue Damage
19%
Treatment Strategy
18%
Prognostic Impact
18%
Autoimmunity
18%
Corticosteroids
18%
Chimeric Antigen Receptor T Cells (CAR-T)
18%
Cell Therapy
18%
Stem Cells
18%
Recurrence Risk
18%
Replication Speed
18%
P53 Abnormal
17%
Tissue Sampling
17%
Overexpression
17%
Cancer Registry
17%
PORTEC
17%
Cytokine Release Syndrome
16%
Retinoblastoma Protein
16%
Endometrial Carcinoma
16%
Protein Loss
16%
Calciprotein Particles
16%
Vascular Remodeling
16%
Chronic Kidney Disease
16%
Particle Counting
16%
Tissue-resident Memory T Cells
16%
Systemic Amyloidosis
16%
Positron Emission Tomography
16%
Severe Hyperglycemia
16%
Abdominal Fat Tissue
16%
Glutamate-cysteine Ligase Catalytic Subunit
16%
Anemia
16%
Brentuximab Vedotin
16%
Previously Untreated Patients
16%
Polytherapy
16%
Iron Deficiency Anemia
16%
Immunochemotherapy
16%
Consolidation Therapy
16%
Treatment Outcome
16%
Histiocytic Disorders
16%
Peripheral T-cell Lymphoma
16%
Primary Central Nervous System Lymphoma (PCNSL)
16%
Cell Infusion
16%
Recurrence Prediction
16%
Continuous Glucose Monitoring
16%
Muscle Strength
16%
Immune Checkpoint Blockade
16%
Immunoglobulin Heavy Chain
16%
T-cell Large Granular Lymphocytic Leukemia
16%
Iron Deficiency
16%
Ibrutinib
16%
R-miniCHOP
16%
Patient-reported Outcomes
16%
ImmunoPET
16%
Melanoma
16%
Mantle Cell Lymphoma
16%
Superiority Trial
16%
Clinical Characteristics
16%
High-grade Serous Ovarian Cancer (HGSOC)
16%
Tumor Metabolism
16%
CD103
16%
Clinical Survival
16%
Lymphoma Cells
16%
Volume Prior
16%
Immunological Biomarkers
16%
Phase I Study
16%
Non-responders
16%
Immunology and Microbiology
B Cell
100%
Tumor Cell
46%
Positron Emission Tomography
43%
Immunotherapy
38%
Macrophage
37%
Lymphoma Cell
32%
Mechanical Stress
32%
Genomic Instability
32%
Monospecific Antibody
32%
T Cell
31%
Immunity
27%
Cancer Cell
27%
Organoid
25%
Cycline
24%
Inflammation Response
23%
DNA Replication
22%
Interleukin 6
21%
Cytotoxicity
21%
DNA Damage
21%
Autoimmunity
21%
Axicabtagene Ciloleucel
20%
Cytokine Release Syndrome
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Immunocompetent Cell
20%
Dynamics
20%
Immune Response
19%
Tumor Volume
19%
Low Drug Dose
19%
Gene Expression Profiling
18%
Cetuximab
18%
Oncogene C Myc
18%
Neck
18%
Tumor Necrosis Factor
18%
Cyclophosphamide
18%
Cancer Immunotherapy
18%
Signal Transduction
17%
Inflammatory Disorder
17%
Cytokine
17%
Gene Expression
17%
P53
16%
Enhancer Region
16%
Selenium Blood Level
16%
Metabolism
16%
Transplant Procedure
16%
Enzyme Active Site
16%
MYD88
16%
Tumor Immunity
16%
Blood Plasma
16%
Cell Phagocytosis
16%
Droplet Digital Polymerase Chain Reaction
16%
Memory T Cell
16%
Immunoglobulin Heavy Chain
16%
Transcriptomics
16%
Memory B Cell
16%
Clustered Regularly Interspaced Short Palindromic Repeat
16%
Bursitis
16%
Chimeric Antigen Receptor T-Cell
16%
Mismatch Repair
16%
Gene Interaction
16%
Skinfold
16%
Fiber Optics
16%
Radiation Field
16%
Rheumatic Polymyalgia
16%
Mitophagy
16%
CD20
16%
Conformation
16%
Time Factor
16%
Trastuzumab
16%
Granulocyte Macrophage Colony-Stimulating Factor
16%
Mouth Mucosa
16%
Fibroblast
16%
Gross Tumor Volume
16%
Immune Cell Infiltration
16%
Cancer Tissue
16%
Cells by Function
16%
Stem Cell Factor
16%
Cortisol
16%
Salivary Gland
16%
Viral Disease
16%
Leporidae
16%
Chromatin Assembly and Disassembly
16%
Immune Disorder
16%
Brain Cell
16%
Pemphigus vulgaris
16%
Interleukin 17
16%
Peptidoglycan
16%
Calorie
16%
Disease Burden
16%
Immune System Disorders
16%
Brain Region
16%
CD40 Ligand
16%
Lifespan
16%
Immune Evasion
15%
Extracellular Matrix
14%
CD79B
14%
Rituximab
14%
Cell Line
13%
Copy Number Variation
12%
RNA Sequence
11%
Antibody Mediated Rejection
11%